6,9-Dioxabicyclo[3.2.2]nonane-7,8-dione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酯类
• 英文名称: 6,9-Dioxabicyclo[3.2.2]nonane-7,8-dione
• 英文别名: 6,9-dioxabicyclo[3.2.2]nonane-7,8-dione
• 化学式: C₇H₈O₄
• 分子量: 156.14
• InChiKey: FVCCMJQHHIFLPI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• DURABLE ANALGETIC SEBACOYL DINALBUPHINE ESTER-PLGA CONTROLLED RELEASE FORMULATION
  申请人：Hu, Oliver Yaopu

  公开号：EP2910242A1

  公开（公告）日：2015-08-26

  The present invention provides a composition comprising nalbuphine prodrug- Sebacoyl dinalbuphine ester and pharmaceutical biodegradable polymer PLGA. The composition is prepared as a controlled release formulation, which can be implanted in a human body, and the formulation is lozenge, capsule, soft capsule, pill, suspension, microsphere, oral implant, emulsified injection, implant or others. The controlled release formulation significantly improves the dosage of common nalbuphine injection, the composition for four times to six times daily administration is improved to once half a month or several months administration, and that is one of the characteristic and effect of the invention. By in vivo tests, the present invention confirmed the pharmacokinetic properties of controlled release formulation, and evaluated effective duration time, the controlled release formulation is used to improve the dosage of common nalbuphine injection.

  本发明提供了一种由纳布啡原药--西巴甲酰二纳布啡酯和药用生物可降解聚合物PLGA组成的组合物。该组合物制备成控释制剂，可植入人体，剂型有锭剂、胶囊、软胶囊、丸剂、混悬剂、微球、口服植入剂、乳化注射剂、植入剂等。控释制剂明显改善了普通纳布啡注射液的用量，将每天给药四次至六次的组合物改善为半个月或几个月给药一次，这也是本发明的特点和效果之一。本发明通过体内试验，证实了控释制剂的药代动力学特性，并对有效持续时间进行了评价，控释制剂用于改善普通纳布啡注射液的剂量。
• Anyhydrous compositions of mTOR inhibitors and methods of use
  申请人：PALVELLA THERAPEUTICS, INC.

  公开号：US10722499B2

  公开（公告）日：2020-07-28

  Disclosed herein are compositions and methods for topical delivery of mTOR inhibitors. In one embodiment, an anhydrous composition includes one or more mTOR inhibitors, one or more solvents, one or more gelling agents, and one or more antioxidants. Also disclosed herein are methods to treat skin disorders using such compositions.

  本文公开了局部给药 mTOR 抑制剂的组合物和方法。 在一个实施方案中，无水组合物包括一种或多种 mTOR 抑制剂、一种或多种溶剂、一种或多种胶凝剂和一种或多种抗氧化剂。 本文还公开了使用此类组合物治疗皮肤疾病的方法。
• Anhydrous compositions of mTOR inhibitors and methods of use
  申请人：PALVELLA THERAPEUTICS, INC.

  公开号：US11000513B2

  公开（公告）日：2021-05-11

  Disclosed herein are compositions and methods for topical delivery of mTOR inhibitors. In one embodiment, an anhydrous composition includes one or more mTOR inhibitors, one or more solvents, one or more gelling agents, and one or more antioxidants. Also disclosed herein are methods to treat skin disorders using such compositions.

  本文公开了局部给药 mTOR 抑制剂的组合物和方法。在一个实施方案中，无水组合物包括一种或多种 mTOR 抑制剂、一种或多种溶剂、一种或多种胶凝剂和一种或多种抗氧化剂。本文还公开了使用此类组合物治疗皮肤疾病的方法。
• SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE
  申请人：Qrono, Inc.

  公开号：EP3373907A1

  公开（公告）日：2018-09-19
• SUSTAINED RELEASE COMPOSITIONS OF KAPPA-OPIOID RECEPTOR AGONIST
  申请人：JT Pharmaceuticals, Inc.

  公开号：EP3463306A1

  公开（公告）日：2019-04-10